pI: 10.3432 |
Length (AA): 307 |
MW (Da): 35602 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
90 | 169 | 1qd7 (I) | 5 | 84 | 33.00 | 0.000000000019 | 0.68 | 0.447586 | 1.78 |
95 | 176 | 1i94 (Q) | 7 | 92 | 32.00 | 0 | 0.74 | 0.480701 | 1.1 |
127 | 222 | 1lc0 (A) | 100 | 197 | 31.00 | 0.21 | 0.02 | 0.265504 | 2.23 |
172 | 292 | 5cwn (A) | 91 | 206 | 16.00 | 0.79 | 0.26 | 0.579137 | -0.92 |
184 | 287 | 5cwj (A) | 2 | 104 | 16.00 | 0.5 | 0.16 | 0.587762 | -1.26 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_128969)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G49400 | protein EMBRYO DEFECTIVE 1129 |
Arabidopsis thaliana | AT3G18880 | Nucleic acid-binding, OB-fold-like protein |
Arabidopsis thaliana | AT1G79850 | 30S ribosomal protein S17 |
Candida albicans | CaO19.4176 | likely mitochondrial ribosomal protein similar to S. cerevisiae MRPS17 (YMR188C) small subunit protein S17 |
Candida albicans | CaO19.11652 | likely mitochondrial ribosomal protein similar to S. cerevisiae MRPS17 (YMR188C) small subunit protein S17 |
Chlamydia trachomatis | CT_519 | 30S ribosomal protein S17 |
Dictyostelium discoideum | DDB_G0277195 | ribosomal protein S17, mitochondrial |
Escherichia coli | b3311 | 30S ribosomal subunit protein S17 |
Leishmania braziliensis | LbrM.34.3830 | 30S Ribosomal protein S17-like protein |
Leishmania donovani | LdBPK_353890.1 | 30S Ribosomal protein S17-like protein |
Leishmania infantum | LinJ.35.3890 | 30S Ribosomal protein S17-like protein |
Leishmania major | LmjF.35.3850 | 30S Ribosomal protein S17-like protein |
Leishmania mexicana | LmxM.34.3850 | 30S Ribosomal protein S17-like protein |
Mycobacterium leprae | ML1854c | PROBABLE 30S RIBOSOMAL PROTEIN S17 RPSQ |
Mycobacterium tuberculosis | Rv0710 | 30S ribosomal protein S17 RpsQ |
Mycobacterium ulcerans | MUL_0799 | 30S ribosomal protein S17 |
Oryza sativa | 4337506 | Os04g0691600 |
Oryza sativa | 4345370 | Os08g0359600 |
Saccharomyces cerevisiae | YMR188C | mitochondrial 37S ribosomal protein MRPS17 |
Trypanosoma brucei gambiense | Tbg972.9.6740 | 30S Ribosomal protein S17, putative |
Trypanosoma brucei | Tb927.9.11300 | Mitochondrial ribosomal protein S17 |
Trypanosoma cruzi | TcCLB.508461.420 | 30S Ribosomal protein S17, putative |
Treponema pallidum | TP0198 | 30S ribosomal protein S17 |
Wolbachia endosymbiont of Brugia malayi | Wbm0332 | 30S ribosomal protein S17 |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.211.2580 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb09.211.2580 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb09.211.2580 this record | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb09.211.2580 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
b3311 | Escherichia coli | essential | goodall |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.